Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly
- 1 May 2016
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 174 (5) , 651-662
Abstract
Objective: The high expression of somatostatin receptor subtype 2 (SSTR2 also known as sst2) usually present in growth hormone (GH)-secreting adenomas is the rationale for therapy with somatostatin analogs (SSAs) in acromegaly. Although SSTR2 expression is a good predictor for biochemical response to SSA treatment, we still face tumors resistant to SSAs despite high SSTR2 expression. Recently, beta-arrestins (β-arrestins) have been highlighted as key players in the regulation of SSTR2 function.Design: To investigate whether β-arrestins might be useful predictors of responsiveness to long-term SSA treatment in acromegaly, we retrospectively evaluated 35 patients with acromegaly who underwent adenomectomy in two referral centers in The Netherlands.Methods: β-arrestin mRNA levels were evaluated in adenoma samples, together with SSTR2 (and SSTR5) mRNA and protein expression. Biochemical response to long-term SSA treatment (median 12 months) was assessed in 32 patients.Results: β-arrestin 1 and 2 mRNA was significantly lower in adenoma tissues from patients who achieved insulin-like growth factor 1 normalization (P= 0.024 andP= 0.047) and complete biochemical control (P= 0.047 andP= 0.039). The SSTR2 mRNA was higher in SSA responder patients compared with the resistant ones (P= 0.026). This difference was more evident when analyzing the SSTR2/β-arrestin 1 and SSTR2/β-arrestin 2 ratio (P= 0.011 andP= 0.010). β-arrestin 1 and 2 expression showed a significant trend of higher median values from full responders, partial responders to resistant patients (P= 0.045 andP= 0.021, respectively). Interestingly, SSTR2 protein expression showed a strong inverse correlation with both β-arrestin 1 and 2 mRNA (ρ= –0.69,P= 0.0011 andρ= –0.67,P= 0.0016).Conclusions: Low β-arrestin expression and high SSTR2/β-arrestin ratio correlate with the responsiveness to long-term treatment with SSAs in patients with acromegaly.Keywords
This publication has 42 references indexed in Scilit:
- Glucocorticoids regulate arrestin gene expression and redirect the signaling profile of G protein-coupled receptorsProceedings of the National Academy of Sciences, 2012
- β-arrestin-mediated receptor trafficking and signal transductionTrends in Pharmacological Sciences, 2011
- Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling PathwaysMolecular Endocrinology, 2010
- Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionPituitary, 2009
- Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegalyInternational Journal of Cancer, 2009
- Expression and Functional Analysis of Dopamine Receptor Subtype 2 and Somatostatin Receptor Subtypes in Canine Cushing’s DiseaseEndocrinology, 2008
- The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenomaClinical Endocrinology, 2007
- Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin AnalogsMolecular Pharmacology, 2005
- β‐Arrestin is involved in the desensitization but not in the internalization of the somatostatin receptor 2A expressed in CHO cellsFEBS Letters, 2002
- Selective Regulation of Endogenous G Protein-coupled Receptors by Arrestins in HEK293 CellsJournal of Biological Chemistry, 2000